TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1997515
Drug: 13‐min insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13‐min insulin pulses (1.3 mU kg‐1 min‐1, 2 min on and 11 min off)
Study: 1997515
Drug: 26‐min insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 26‐min insulin pulses (2.6 mU kg‐1 min‐1, 2 min on and 24 min off)
Study: 1997515
Drug: Continuous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous insulin (0.2 mU kg‐1 min‐1)
Study: 6555065
Drug: Dexamethasone administration
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone administration for 3 days
Study: 31242981
Drug: Tualang honey
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tualang honey 20mg daily for 8 weeks
Study: 31242981
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 100mg daily for 8 weeks
Study: 27206952
Drug: Icosapent ethyl
Normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Icosapent ethyl 4 g/day (MARINE)
Study: 27206952
Drug: Icosapent ethyl
Normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Icosapent ethyl 4 g/day (ANCHOR)
Study: 27206952
Drug: Icosapent ethyl
Normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Icosapent ethyl 4 g/day (ANCHOR, higher-efficacy group)
Study: 27206952
Drug: Icosapent ethyl
Normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Icosapent ethyl 4 g/day (ANCHOR, medium-efficacy group)
Study: 19514187
Drug: NGF injection
Normalized name: Panthenol 1 g in 100 mL TOPICAL SOLUTION [NGF 574H HAIR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGF injection at Yifeng (TE 17) and Wangu (GB 12)
Study: 19514187
Drug: Xibiling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xibiling and adenosine triphosphate (ATP) orally, and intramuscular injection with VB1 and VB12
Study: 17766700
Drug: Enzastaurin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzastaurin (single doses 2-400 mg)
Study: 17766700
Drug: Enzastaurin (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzastaurin (multiple doses 25-400 mg)
Study: 7909866
Drug: Postoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative treatment with 500 mg of 17‐1A antibody, followed by four 100 mg infusions each month
Study: 27451879
Drug: Rikkunshito (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rikkunshito (2.5 g before every meal for 48 weeks)
Study: 22419702
Drug: Metformin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1000 mg two times daily for obese women; 500 mg + 1000 mg daily for nonobese)
Study: 22419702
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical doses)
Study: 22419702
Drug: Metformin (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (in obese women)
Study: 22419702
Drug: Metformin (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (in nonobese women)
Study: 22419702
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus standard infertility treatment
Study: 19669678
Drug: Ranibizumab (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (monthly administration)
Study: 16192479
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg every 12 hours)
Study: 10823763
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of prophylaxis (n=355)
Study: 8651713
Drug: 8% glycolic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% glycolic acid cream
Study: 8651713
Drug: 8% L-lactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% L-lactic acid cream
Study: 1995051
Drug: Lignocaine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 1.5 mg/kg intravenously prior to induction
Study: 31722941
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 540,000 IU cholecalciferol followed by 4000 IU daily for 90 days
Study: 22726885
Drug: Prothrombin complex
Normalized name: prothrombin complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prothrombin complex concentrate (PCC) administered at a dose of ≥20 UI/kg with vitamin K
Study: 22726885
Drug: Prothrombin complex
Normalized name: prothrombin complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prothrombin complex concentrate (PCC) administered at a dose of >20 UI/kg
Study: 22726885
Drug: Prothrombin complex
Normalized name: prothrombin complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prothrombin complex concentrate (PCC) administration
Study: 16889639
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone pulse (IVGC)
Study: 16889639
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone (OGC)
Study: 12519218
Drug: AOC7 (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: AOC7 (1000 mg amoxicillin, 20 mg omeprazole, and 500 mg clarithromycin twice daily for 7 days)
Study: 12519218
Drug: FOT4 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOT4 (200 mg furazolidone, 20 mg omeprazole, and 500 mg tetracycline twice daily for 4 days)
Study: 12519218
Drug: FOT7 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOT7 (200 mg furazolidone, 20 mg omeprazole, and 500 mg tetracycline twice daily for 7 days)
Study: 8892160
Drug: Surgery after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery after failed behavioral treatment
Study: 31767474
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy with 66 Gy (24x2.75 Gy) and low dose Cisplatin +/− Cetuximab
Study: 31767474
Drug: Post-treatment PET-metrics
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment PET-metrics (SUVmax, SUVmean, MTV, TLG)
Study: 28003538
Drug: Whey Protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey Protein supplementation (0, 20, 40, or 60 g WP/d)
Study: 26030325
Drug: Add-on alirocumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on alirocumab 75 mg every 2 weeks (Q2W)
Study: 26030325
Drug: Add-on ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Add-on ezetimibe 10 mg/d
Study: 26030325
Drug: Switching atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching atorvastatin 40 mg to rosuvastatin 40 mg
Study: 20354035
Drug: sivelestat 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: sivelestat 0.2 mg/kg/h
Study: 10706930
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (long‐cycle transdermal 17‐beta‐estradiol 50 microg/24 hour for 3 months with sequential medroxy‐progesterone acetate for 14 days)
Study: 8931030
Drug: Twice-weekly structured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly structured exercise program
Study: 6430329
Drug: Amino acids
Normalized name: Amino acids
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acids (L‐cysteine, glycine, DL‐threonine)
Study: 24176943
Drug: Early initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early initiation of antiretroviral therapy (ART) during TB treatment
Study: 24176943
Drug: Late initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Late initiation of antiretroviral therapy (ART) during TB treatment
Study: 20578825
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) replacement therapy for one year
Study: 12439223
Drug: bupropion (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupropion (300 mg/day for 10 weeks)
Study: 9579500
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine (4 microg/kg) with glucose-free solution
Study: 9579500
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 2% glucose with clonidine
Study: 7650232
Drug: Venlafaxine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (50 mg every 8 hours for 10 days)
Study: 7650232
Drug: Diazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (10 mg single dose on day 5)
Study: 2669089
Drug: Dexfenfluramine 15
Normalized name: dexfenfluramine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexfenfluramine 15 mg b.d.
Study: 975730
Drug: Cefamandole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole (1 gm intravenous)
Study: 975730
Drug: Cephalothin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalothin (1 gm intravenous)
Study: 975730
Drug: Cefamandole and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole and Cephalothin (both drugs)
Study: 27996097
Drug: Infection-preventive technique
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infection-preventive technique including povidone-iodine, double gloving, meticulous aseptic/antiseptic measures, and antibiotic prophylaxis.
Study: 24139127
Drug: Higenamine-based dietary
Normalized name: Higenamine
DrugBank: Higenamine (DB12779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higenamine-based dietary supplement (including caffeine 270 mg and yohimbe bark extract)
Study: 9427706
Drug: Desmopressin (DDAVP)
Normalized name: desmopressin Injection [DDAVP]
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Desmopressin (DDAVP) infusion at stepwise doses of 0.7, 7.0, and 70 ng/min
Study: 9427706
Drug: Constant-rate DDAVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant-rate DDAVP infusion at 70 ng/min for 20 minutes
Study: 9427706
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (SNP) infusion at doses of 0.5, 2.5, and 10 micrograms/min
Study: 9427706
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (dominant arm) during constant-rate DDAVP infusion
Study: 27112096
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of treatment by a specialist physiotherapist
Study: 7646915
Drug: Hormonal or
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal or chemotherapy
Study: 7646915
Drug: Radio/chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radio/chemotherapy
Study: 346356
Drug: Pindolol 5
Normalized name: pindolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol 5 mg (single oral dose)
Study: 346356
Drug: Salbutamol (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (conventional therapeutic dose by inhalation)
Study: 28787738
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (weight loss treatment)
Study: 23600983
Drug: Cevimeline 30
Normalized name: Cevimeline 30mg Oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cevimeline 30 mg three times a day for four weeks
Study: 23600983
Drug: Pilocarpine 5
Normalized name: PILOCARPINE 5MG/UNT OPH,CRC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine 5 mg three times a day for four weeks
Study: 19405969
Drug: High Intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Intensity Treatment (HIT)
Study: 19405969
Drug: Low Intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Intensity Treatment (LIT)
Study: 16931871
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine pre-treatment
Study: 15303766
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg isosorbide dinitrate (sustained-release)
Study: 31970477
Drug: Minodronate (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minodronate (50 mg/4 weeks) plus alfacalcidol (1 μg/day)
Study: 31970477
Drug: Alfacalcidol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol (1 μg/day)
Study: 23060624
Drug: NVA237 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVA237 50 μg
Study: 18666494
Drug: All active
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All active bleaching agents (including 10% carbamide peroxide with potassium nitrate)
Study: 16129870
Drug: Patient decision
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient decision aid (self-administered booklet and audiotape tailored to personal stroke risk profile)
Study: 10786195
Drug: Topotecan 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan 1.5 mg/m2 on 5 consecutive days every 3 weeks
Study: 10786195
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of topotecan 0.3 to 0.5 mg/m2
Study: 10786195
Drug: Topotecan 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan 1.5 mg/m2/day for 5 consecutive days every 21 days
Study: 1997045
Drug: Clonidine 7
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 7 micrograms kg‐1 i.v. infusion over 120 min
Study: 6386760
Drug: Hyperfractionated radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiotherapy with misonidazole (12 g/m2 daily in 1.2 g/m2 fractions)
Study: 19411388
Drug: naproxcinod 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxcinod 750 mg once daily (qd)
Study: 19411388
Drug: naproxcinod 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxcinod 750 mg twice daily (bid)
Study: 19411388
Drug: naproxcinod 1125
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxcinod 1125 mg bid
Study: 14693981
Drug: Troglitazone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (200 mg for 12 weeks)
Study: 9852438
Drug: Blue filter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blue filter treatment (flash stimulation with a blue filter during occlusion of the better eye for one hour daily)
Study: 9852438
Drug: Blue filter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blue filter treatment
Study: 9852438
Drug: Classical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classical treatment (full time total occlusion by patch)
Study: 7989814
Drug: Perioperative, high-dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative, high-dosage antibiotic administration
Study: 7989814
Drug: Existing prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Existing prophylactic regimen with longer intervals and postoperative antibiotics for 7 to 10 days
Study: 3802604
Drug: Sublingual nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual nifedipine 10 mg
Study: 2690788
Drug: Oral captopril
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral captopril 50 mg
Study: 26439038
Drug: Progesterone vaginal
Normalized name: progesterone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone vaginal suppositories (400 mg, 200 mg 2 times per day) + Alpha Lipoic Acid (ALA) (600 mg, 300 mg 2 times per day)
Study: 26439038
Drug: Progesterone vaginal
Normalized name: progesterone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone vaginal suppositories (400 mg, 200 mg 2 times per day)
Study: 21070328
Drug: IPI implants
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IPI implants
Study: 21070328
Drug: I‐Plant implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: I‐Plant implants
Study: 21070328
Drug: Both implant
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both implant systems (IPI and I‐Plant)
Study: 21070328
Drug: Transitional implants
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transitional implants with good primary stability
Study: 21070328
Drug: Gender, kind
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gender, kind of superstructure, location of the implant, tooth status of the opposing jaw, immediate prosthetic superstructure
Study: 17273661
Drug: Thalidomide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (300 mg daily for 30 days)
Study: 17273661
Drug: Pentoxifylline (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (1.2 g daily for 30 days)
Study: 9534995
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose at 1 year of age
Study: 7723004
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of assessment measures
Study: 2845707
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) 5000 anti-XaU injected every 24 hours
Study: 2845707
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UH) 5000 IU injected every 12 hours
Study: 30366741
Drug: 1:1.5 carbohydrate‐protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1:1.5 carbohydrate‐protein supplement (16g CHO/25g PRO) pre-training (PRE)
Study: 30366741
Drug: 1:1.5 carbohydrate‐protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1:1.5 carbohydrate‐protein supplement (16g CHO/25g PRO) post-training (POST)
Study: 30366741
Drug: No supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supplement (CON)
Study: 29468530
Drug: Biomarker-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomarker-guided therapy using NT-proBNP
Study: 24841833
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 μg once daily via HandiHaler
Study: 21964557
Drug: Repetitive leftward
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive leftward optokinetic stimulation (OKS) with smooth pursuit eye movements as therapy.
Study: 21964557
Drug: Visual scanning
Normalized name: chlorpheniramine tannate Oral Tablet [Ed Chlor Tan]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visual scanning therapy.
Study: 17559376
Drug: Somatostatin infusion
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin infusion for 12 hours (SOM1)
Study: 17559376
Drug: Gabexate infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabexate infusion for 12 hours (GAB1)
Study: 17559376
Drug: Somatostatin infusion
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin infusion for less than 12 hours (SOM2)
Study: 17559376
Drug: Gabexate infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabexate infusion for less than 12 hours (GAB2)
Study: 10597956
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplement (2.5 mg or 1.0 mg)
Study: 8598594
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (one of four regimens: streptokinase with subcutaneous heparin; streptokinase with intravenous heparin; streptokinase plus alteplase with intravenous heparin; accelerated alteplase with intravenous heparin)
Study: 6113192
Drug: Cimetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 200 mg tds and 400 mg nocte
Study: 31126541
Drug: Salix extract
Normalized name: SALIX
DrugBank: Willow bark (DB14691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salix extract (400 mg daily)
Study: 31126541
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefenamic acid (750 mg daily)
Study: 25052890
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of folic acid added to ADM for 12 weeks
Study: 23171320
Drug: IFCR‐L (Intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFCR‐L (Intermittent fasting combined with calorie restriction and liquid diet)
Study: 23171320
Drug: IFCR‐L
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFCR‐L
Study: 16304073
Drug: Enoxaparin (consistent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (consistent therapy)
Study: 16304073
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (consistent therapy)
Study: 11967499
Drug: CEE plus
Normalized name: Ecee Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE plus medroxyprogesterone acetate (MPA) 2.5 mg
Study: 2654254
Drug: Ketotifen (Zaditen;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (Zaditen; Sandoz Pharmaceuticals, Basel, Switzerland)
Study: 26028120
Drug: Continued methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued methadone treatment
Study: 23447518
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human GH (rhGH) therapy
Study: 19133062
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of diclofenac (30 mg total from two tapes)
Study: 19133062
Drug: Oral application
Normalized name: Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral application of diclofenac (37.5 mg capsule)